Reduced intravenous glutathione in the treatment of early Parkinson's disease
We understand the biochemistry, know the therapeutic applications, and provide the medical supervision that makes high-dose therapy both safe and effective
Presently, BPC 157 therapy has still limited but encouraging clinical evidence (no toxicity in clinical trials (i.e., effective in ulcerative colitis, phase II) and toxicology studies without lethal dose (LD1)), and much more should be further achieved [1,2,3,4,5,6,7,8,9,10,11]
It is important to warm the vial using body heat only
Oxidised glutathione (GSSG) is the "spent" form that needs to be converted back to GSH before it can function